State Street
TSHA icon

State Street’s Taysha Gene Therapies TSHA Stock Holding History

State Street’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.8M Buy
11,421,920
+212,842
+2% +$1.26M ﹤0.01% 1620
2026
Q1 		$50.1M Buy
11,209,078
+418,994
+4% +$1.95M ﹤0.01% 1740
2025
Q4 		$59.3M Buy
10,790,084
+3,553,619
+49% +$17.3M ﹤0.01% 1643
2025
Q3 		$23.7M Buy
7,236,465
+2,098,155
+41% +$5.94M ﹤0.01% 2143
2025
Q2 		$11.9M Buy
5,138,310
+1,904,798
+59% +$4.14M ﹤0.01% 2485
2025
Q1 		$4.49M Sell
3,233,512
-3,240,855
-50% -$5.42M ﹤0.01% 2926
2024
Q4 		$11.2M Buy
6,474,367
+3,005,299
+87% +$6.23M ﹤0.01% 2560
2024
Q3 		$6.97M Buy
3,469,068
+150,647
+5% +$331K ﹤0.01% 2803
2024
Q2 		$7.43M Buy
3,318,421
+2,978,901
+877% +$8.67M ﹤0.01% 2739
2024
Q1 		$974K Buy
339,520
+196,300
+137% +$409K ﹤0.01% 3478
2023
Q4 		$253K Buy
143,220
+3,200
+2% +$6.38K ﹤0.01% 3840
2023
Q3 		$442K Buy
140,020
+25,100
+22% +$46.9K ﹤0.01% 3696
2023
Q2 		$76K Hold
114,920
– – ﹤0.01% 4296
2023
Q1 		$91.7K Hold
114,920
– – ﹤0.01% 4344
2022
Q4 		$260K Buy
114,920
+37,500
+48% +$75.9K ﹤0.01% 4009
2022
Q3 		$149K Hold
77,420
– – ﹤0.01% 4266
2022
Q2 		$288K Sell
77,420
-421,794
-84% -$1.67M ﹤0.01% 4049
2022
Q1 		$3.25M Buy
499,214
+35,045
+8% +$262K ﹤0.01% 3377
2021
Q4 		$5.41M Buy
464,169
+111,983
+32% +$1.69M ﹤0.01% 3203
2021
Q3 		$6.56M Buy
352,186
+33,567
+11% +$638K ﹤0.01% 3093
2021
Q2 		$6.75M Buy
318,619
+196,478
+161% +$4.53M ﹤0.01% 3106
2021
Q1 		$2.48M Buy
122,141
+12,035
+11% +$326K ﹤0.01% 3348
2020
Q4 		$2.92M Buy
+110,106
New +$2.37M ﹤0.01% 3204

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

State Street's TSHA Position: Q2 2026 in Review

State Street increased its Taysha Gene Therapies (TSHA) stake by 1.9% in Q2 2026, buying an estimated $1.26M and bringing the position to 11,421,920 shares worth $77.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1620.

State Street first reported a position in TSHA in Q4 2020 and has held it in 23 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • State Street held 11,421,920 shares of Taysha Gene Therapies worth $77.8M as of Q2 2026.
  • State Street bought 212,842 Taysha Gene Therapies shares in Q2 2026, an estimated $1.26M.
  • Taysha Gene Therapies made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1620 holding.
  • State Street first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 23 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.